Fragmenting the platelet to reduce metastasis

Blood. 2012 Oct 4;120(14):2779-80. doi: 10.1182/blood-2012-08-450072.

Abstract

In this issue of Blood, Zhang et al describe an antiplatelet reagent attacking metastasis, the most deadly aspect of cancer.(1) Their experiments outline an early-stage preclinical approach providing proof-of-principle for antiplatelet strategies that may ultimately lead to an improved prognosis for the cancer patient.(1)

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Carcinoma, Lewis Lung / prevention & control*
  • Female
  • Humans
  • Melanoma, Experimental / prevention & control*
  • Platelet Activation / immunology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / immunology*
  • Single-Chain Antibodies / therapeutic use*
  • Tumor Microenvironment / immunology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Single-Chain Antibodies